Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010, The Lancet, vol.382, issue.9904, pp.1575-86, 2009. ,
DOI : 10.1016/S0140-6736(13)61611-6
Definition and description of schizophrenia in the DSM-5, Schizophrenia Research, vol.150, issue.1, pp.3-10, 2013. ,
DOI : 10.1016/j.schres.2013.05.028
Cognition in Schizophrenia: Impairments, Determinants, and Functional Importance, Psychiatric Clinics of North America, vol.28, issue.3, pp.613-646, 2005. ,
DOI : 10.1016/j.psc.2005.05.004
Medical Morbidity and Mortality in Schizophrenia, The Journal of Clinical Psychiatry, vol.66, issue.02, 2005. ,
DOI : 10.4088/JCP.v66n0205
Symptomatic and Functional Recovery From a First Episode of Schizophrenia or Schizoaffective Disorder, American Journal of Psychiatry, vol.161, issue.3, pp.473-482, 2004. ,
DOI : 10.1176/appi.ajp.161.3.473
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009. ,
DOI : 10.1016/S0140-6736(08)61764-X
DRUG-INDUCED PARKINSONISM IN THE ELDERLY, The Lancet, vol.324, issue.8411, 1984. ,
DOI : 10.1016/S0140-6736(84)91516-2
Drug-Induced Parkinsonism in the Elderly, Drugs & Aging, vol.81, issue.960, pp.105-123, 2012. ,
DOI : 10.2165/11598540-000000000-00000
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, Neurology Apr, vol.1252, issue.6, pp.1976-19901214, 1999. ,
Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment, J Clin Psychiatry, vol.44, issue.1, pp.13-19, 1983. ,
Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism, Journal of Neurology, vol.12, issue.Suppl 7, 2009. ,
DOI : 10.1007/s00415-009-5039-0
I]FP-CIT SPET imaging in drug-induced Parkinsonism, Movement Disorders, vol.40, issue.13, pp.1825-1834, 2008. ,
DOI : 10.1002/mds.22098
123 I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism, Schizophr Res, 2012. ,
Effects of Calcium Antagonists on the Dopamine System, Clinical Neuropharmacology, vol.18, issue.5, pp.410-436, 1995. ,
DOI : 10.1097/00002826-199510000-00004
MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies, J Pharmacol Exp Ther, vol.268, issue.1, pp.380-387, 1994. ,
heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity, Movement Disorders, vol.132, issue.1, pp.41-53, 2014. ,
DOI : 10.1002/mds.25724
Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, pp.437-483, 1997. ,
DOI : 10.1037/0894-4105.11.3.437
Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder, The Journal of Clinical Psychiatry, vol.67, issue.10, p.12, 2006. ,
DOI : 10.4088/JCP.1006e12
The global cognitive impairment in schizophrenia: consistent over decades and around the world Social cognition in schizophrenia, Schizophr Res. Nat Rev Neurosci, vol.150, issue.20, pp.42-50, 2013. ,
Social cognition and quality of life in schizophrenia, Schizophrenia Research, vol.137, issue.1-3, pp.1-3212 ,
DOI : 10.1016/j.schres.2012.02.017
Depression in Schizophrenia: Perspective in the Era of ???Atypical??? Antipsychotic Agents, American Journal of Psychiatry, vol.157, issue.9, pp.1379-89, 2000. ,
DOI : 10.1176/appi.ajp.157.9.1379
Les maladies dépressives Paris : Flammarion, Médecine-sciences A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence. JAMA Psychiatry, pp.133-42135, 2003. ,
Development of social functioning in preschizophrenia children and adolescents: A systematic review., Psychological Bulletin, vol.134, issue.4, pp.561-83, 2008. ,
DOI : 10.1037/0033-2909.34.4.561
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis, The British Journal of Psychiatry, vol.205, issue.2 ,
DOI : 10.1192/bjp.bp.113.127753
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment, Archives of General Psychiatry, vol.69, issue.8, pp.776-86, 2012. ,
DOI : 10.1001/archgenpsychiatry.2012.169
Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging, Current Pharmaceutical Design, vol.15, issue.22, pp.2550-2559, 2009. ,
DOI : 10.2174/138161209788957528
URL : http://doi.org/10.2174/138161209788957528
Increased dopamine transmission in schizophrenia: relationship to illness phases, Biological Psychiatry, vol.46, issue.1, pp.56-72, 1999. ,
DOI : 10.1016/S0006-3223(99)00067-0
Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study, Molecular Psychiatry, vol.16, issue.9, 2011. ,
DOI : 10.1001/archpsyc.59.10.921
A Longitudinal Examination of the Neurodevelopmental Impact of Prenatal Immune Activation in Mice Reveals Primary Defects in Dopaminergic Development Relevant to Schizophrenia, Journal of Neuroscience, vol.30, issue.4, pp.1270-87, 2010. ,
DOI : 10.1523/JNEUROSCI.5408-09.2010
Effects of birth insult and stress at adulthood on in vivo tyrosine hydroxylase and tryptophan hydroxylase activities in rat brain El-Khodor BF, Boksa P. Differential vulnerability of male versus female rats to long-term effects of birth insult on brain catecholamine levels, Exp Neurol, vol.47182, issue.361, pp.87-9208, 2003. ,
Influence of perinatal factors on the nucleus accumbens dopamine response to repeated stress during adulthood: an electrochemical study in the rat, Neuroscience, vol.77, issue.4, pp.1067-76, 1997. ,
DOI : 10.1016/S0306-4522(96)00543-X
Schizophrenia and Migration: A Meta-Analysis and Review, American Journal of Psychiatry, vol.162, issue.1, pp.12-24, 2005. ,
DOI : 10.1176/appi.ajp.162.1.12
URL : http://doi.org/10.1176/appi.ajp.162.1.12
Schizophrenia and Urbanicity: A Major Environmental Influence--Conditional on Genetic Risk, Schizophrenia Bulletin, vol.31, issue.4, pp.795-804, 2005. ,
DOI : 10.1093/schbul/sbi060
URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/31/4/795
Childhood Adversities Increase the Risk of Psychosis: A Meta-analysis of Patient-Control, Prospective- and Cross-sectional Cohort Studies, Schizophrenia Bulletin, vol.38, issue.4, pp.661-71 ,
DOI : 10.1093/schbul/sbs050
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia, Archives of General Psychiatry, vol.66, issue.1, 2009. ,
DOI : 10.1001/archgenpsychiatry.2008.514
Modeling Sensitization to Stimulants in Humans, Archives of General Psychiatry, vol.63, issue.12, pp.1386-951109, 2006. ,
DOI : 10.1001/archpsyc.63.12.1386
A network of dopaminergic gene variations implicated as risk factors for schizophrenia, Human Molecular Genetics, vol.17, issue.5, pp.747-58, 2008. ,
DOI : 10.1093/hmg/ddm347
Autism genetics: emerging data from genome-wide copy-number and single nucleotide polymorphism scans, Expert Review of Molecular Diagnostics, vol.9, issue.8, pp.795-803, 2009. ,
DOI : 10.1586/erm.09.59
Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in Idiopathic Generalized and Focal Epilepsies, PLoS Genetics, vol.23, issue.5, p.1000962, 2010. ,
DOI : 10.1371/journal.pgen.1000962.t002
AKT/GSK3 signaling pathway and schizophrenia, Frontiers in Molecular Neuroscience, vol.5, p.33, 2012. ,
DOI : 10.3389/fnmol.2012.00033
Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry, pp.705-717, 2002. ,
The Cognitive and Affective Structure of Paranoid Delusions, Archives of General Psychiatry, vol.66, issue.3, pp.236-283, 2009. ,
DOI : 10.1001/archgenpsychiatry.2009.1
Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, 2006. ,
DOI : 10.1016/S1474-4422(06)70471-9
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Do environmental toxins cause Parkinson's disease? A critical review, Neurology. Neurology, vol.5440, issue.5210, pp.21-23, 1990. ,
Parkinson's disease in a chemist working with 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine Pesticide exposure and risk for Parkinson's disease, N Engl J Med Ann Neurol, vol.30960, issue.52, pp.310197-203, 1983. ,
Genetics of Parkinson's disease ??? state of the art, 2013, Parkinsonism & Related Disorders, vol.20, issue.1, pp.23-28, 2013. ,
DOI : 10.1016/S1353-8020(13)70009-9
Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment, Movement Disorders, vol.137, issue.6, p.2016 ,
DOI : 10.1016/j.nbd.2015.09.006
The genetics of Parkinson's disease: Progress and therapeutic implications, Movement Disorders, vol.47, issue.Suppl, pp.14-23, 2013. ,
DOI : 10.1002/mds.25249
Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease, Movement Disorders, vol.133, issue.Pt 2, pp.617-643, 2012. ,
DOI : 10.1002/mds.24996
Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms, Adv Neurol, vol.60, pp.140-147, 1993. ,
Consensus Statement of the Movement Disorder Society on Tremor, Movement Disorders, vol.10, issue.S3, pp.2-23, 1998. ,
DOI : 10.1002/mds.870131303
Maladie de Parkinson idiopathique??: aspects cliniques, diagnostiques et th??rapeutiques, EMC - Neurologie, vol.7, issue.2, pp.1-30 ,
DOI : 10.1016/S0246-0378(10)51548-3
Association of olfactory dysfunction with risk for future Parkinson's disease, Annals of Neurology, vol.253, issue.2, pp.167-73, 2008. ,
DOI : 10.1002/ana.21291
Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences, Journal of the Neurological Sciences, vol.310, issue.1-2, pp.133-141, 2011. ,
DOI : 10.1016/j.jns.2011.07.014
Sleep disorders in Parkinson???s disease, Journal of Neurology, vol.245, issue.S1, pp.15-18, 1998. ,
DOI : 10.1007/PL00007731
Freezing of gait and falls in Parkinson's disease, J Park Dis, vol.4, issue.2, pp.255-60, 2014. ,
[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria], Rev Neurol, 2010. ,
Cognitive Dysfunction in Parkinson???s Disease: The Role of Frontostriatal Circuitry, The Neuroscientist, vol.35, issue.15 ,
DOI : 10.1177/1073858404266776
Mild Cognitive Impairment and Parkinson???s Disease - Something to Remember, Journal of Parkinson's Disease, vol.4, issue.4, pp.651-657, 2014. ,
DOI : 10.3233/JPD-140427
URL : http://www.repository.cam.ac.uk/handle/1810/245834
Dementia and mild cognitive impairment in Parkinson's disease: a review]. Rev Neurol, pp.555-69, 2014. ,
New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity, Trends in Pharmacological Sciences, vol.26, issue.8, pp.391-398, 2005. ,
DOI : 10.1016/j.tips.2005.06.007
Protective and toxic roles of dopamine in Parkinson's disease, Journal of Neurochemistry, vol.25, issue.6, pp.898-915 ,
DOI : 10.1111/jnc.12686
Intraneuronal dopamine-quinone synthesis: A review, Neurotoxicity Research, vol.37, issue.6, 2000. ,
DOI : 10.1007/BF03033289
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson's disease, Brain Research, vol.1139, pp.195-200, 2007. ,
DOI : 10.1016/j.brainres.2006.09.100
Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1812, issue.6, pp.663-73, 1812. ,
DOI : 10.1016/j.bbadis.2011.02.013
Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis, Journal of Proteomics, vol.94, pp.202-208, 2013. ,
DOI : 10.1016/j.jprot.2013.07.015
Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species, Journal of Neurochemistry, vol.71, issue.5, pp.2112-2134, 1998. ,
DOI : 10.1046/j.1471-4159.1998.71052112.x
Mitochondria in the aetiology and pathogenesis of Parkinson's disease, The Lancet Neurology, vol.7, issue.1, pp.97-109, 2008. ,
DOI : 10.1016/S1474-4422(07)70327-7
Mitochondrial complex I deficiency in Parkinson's disease, Adv Neurol, vol.60, pp.288-91, 1993. ,
Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease, Brain, vol.132, issue.12, pp.3285-97, 2009. ,
DOI : 10.1093/brain/awp293
Parkinson's disease: animal models and dopaminergic cell vulnerability Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease, Front Neuroanat. Gene, vol.8532, issue.841, pp.15518-15541, 2013. ,
DOI : 10.3389/fnana.2014.00155
URL : http://doi.org/10.3389/fnana.2014.00155
Parkinson's disease and inflammatory changes, Neurotoxicity Research, vol.17, issue.6, pp.411-419, 2003. ,
DOI : 10.1007/BF03033170
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, vol.38, issue.8, pp.1285-91, 1988. ,
DOI : 10.1212/WNL.38.8.1285
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms, Nature Reviews Neuroscience, vol.13, issue.1, pp.57-69, 2007. ,
DOI : 10.1523/JNEUROSCI.4306-04.2005
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders, Free Radical Biology and Medicine, vol.53, issue.4, pp.983-92, 2012. ,
DOI : 10.1016/j.freeradbiomed.2012.05.040
Pathoanatomy of Parkinson???s disease, Journal of Neurology, vol.247, issue.S2, pp.3-10, 2000. ,
DOI : 10.1007/PL00007758
Pathological roles of ??-synuclein in neurological disorders, The Lancet Neurology, vol.10, issue.11, pp.1015-1040, 2011. ,
DOI : 10.1016/S1474-4422(11)70213-7
??-synuclein locus duplication as a cause of familial Parkinson's disease, The Lancet, vol.364, issue.9440, pp.1167-1176, 2004. ,
DOI : 10.1016/S0140-6736(04)17103-1
Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nature Genetics, vol.105, issue.12, 2009. ,
DOI : 10.1038/ng.487
The many faces of ??-synuclein: from structure and toxicity to therapeutic target, Nature Reviews Neuroscience, vol.418, issue.1, pp.38-48, 2013. ,
DOI : 10.1038/nrn3406
??-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proceedings of the National Academy of Sciences, vol.99, issue.16, pp.10813-10821, 2002. ,
DOI : 10.1073/pnas.152339799
??-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress, The American Journal of Pathology, vol.157, issue.2, pp.401-411, 2000. ,
DOI : 10.1016/S0002-9440(10)64553-1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850140
The Role of ??-Synuclein Assembly and Metabolism in the Pathogenesis of Lewy Body Disease, Journal of Molecular Neuroscience, vol.24, issue.3, pp.343-52, 2004. ,
DOI : 10.1385/JMN:24:3:343
Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein, J Alzheimers Dis JAD, 2004. ,
A Pathologic Cascade Leading to Synaptic Dysfunction in ??-Synuclein-Induced Neurodegeneration, Journal of Neuroscience, vol.30, issue.24, pp.8083-95, 2010. ,
DOI : 10.1523/JNEUROSCI.1091-10.2010
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease, Movement Disorders, vol.24, issue.8, pp.1091-1097, 2010. ,
DOI : 10.1002/mds.23012
Gastric ??-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology, Neuroscience Letters, vol.396, issue.1, pp.67-72, 2006. ,
DOI : 10.1016/j.neulet.2005.11.012
Are synucleinopathies prion-like disorders? Lancet Neurol, pp.1128-1166, 2010. ,
DOI : 10.1016/s1474-4422(10)70213-1
Parkinson's disease: a dual-hit hypothesis, Neuropathology and Applied Neurobiology, vol.70, issue.6, pp.599-614, 2007. ,
DOI : 10.1007/s007050050016
Functional architecture of basal ganglia circuits: neural substrates of parallel processing, Trends in Neurosciences, vol.13, issue.7, pp.266-71, 1990. ,
DOI : 10.1016/0166-2236(90)90107-L
Afferent and Efferent Relationships of the Basal Ganglia, Ciba Found Symp, vol.15, pp.3-29, 1984. ,
DOI : 10.1002/9780470720882.ch2
Central dopamine receptors: general considerations (Part 1)], Rev Neurol, vol.160, pp.8-9862, 2004. ,
The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course, Handb Exp Pharmacol, issue.212, pp.1-26, 2012. ,
DOI : 10.1007/978-3-642-25761-2_1
Novel dopamine receptors half a decade later, Trends in Pharmacological Sciences, vol.16, issue.8, pp.270-275, 1995. ,
DOI : 10.1016/S0165-6147(00)89044-6
THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS, Progress in Neurobiology, vol.50, issue.4 ,
DOI : 10.1016/S0301-0082(96)00042-1
Frontal-striatal circuit functions: Context, sequence, and consequence, Journal of the International Neuropsychological Society, vol.9, issue.01, pp.103-130, 2003. ,
DOI : 10.1017/S1355617703910125
The functional anatomy of basal ganglia disorders. Trends Neurosci, pp.366-75, 1989. ,
Extrinsic connections of the basal ganglia. Trends Neurosci, pp.254-262, 1990. ,
The functional role of the subthalamic nucleus in cognitive and limbic circuits, Progress in Neurobiology, vol.76, issue.6, pp.393-413, 2005. ,
DOI : 10.1016/j.pneurobio.2005.09.005
The functional anatomy of disorders of the basal ganglia, Trends in Neurosciences, vol.18, issue.2, pp.63-67, 1995. ,
DOI : 10.1016/0166-2236(95)80020-3
Primate models of movement disorders of basal ganglia origin. Trends Neurosci, pp.281-286, 1990. ,
Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons, Nat Neurosci, vol.3, issue.3, pp.226-256, 2000. ,
A re-evaluation of the current model of the basal ganglia, Parkinsonism & Related Disorders, vol.7, issue.3, pp.193-201, 2001. ,
DOI : 10.1016/S1353-8020(00)00058-4
Parkinsonism following neuroleptic exposure: A double-hit hypothesis? Mov Disord Off J Mov Disord Soc, pp.780-785, 2015. ,
DOI : 10.1002/mds.26209
Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson???s disease, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.Suppl 7, pp.556-64, 2010. ,
DOI : 10.1007/s00259-009-1289-4
Combined use of 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): A 2-year follow-up study, Archives of Gerontology and Geriatrics, vol.56, issue.1, pp.124-132, 2013. ,
DOI : 10.1016/j.archger.2012.05.001
Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort, Neurology, vol.79, issue.15, pp.1615-1636, 2009. ,
DOI : 10.1212/WNL.0b013e31826e25ce
Understanding drug-induced parkinsonism: Separating pearls from oy-sters, Neurology, vol.70, issue.8, pp.32-34, 2008. ,
DOI : 10.1212/01.wnl.0000302255.49113.51
Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research, Journal of Clinical Psychopharmacology, vol.30, issue.1, 2010. ,
DOI : 10.1097/JCP.0b013e3181c914b3
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS, Acta Psychiatrica Scandinavica, vol.45, issue.S212, pp.11-19, 1970. ,
DOI : 10.1111/j.1600-0447.1970.tb02066.x
Clinimetric Evaluation of the Simpson-Angus Scale in Older Adults With Schizophrenia, Journal of Clinical Psychopharmacology, vol.34, issue.1, pp.36-45, 2014. ,
DOI : 10.1097/JCP.0b013e3182a6a2e3
Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population, BMC Neurology, vol.14, issue.1, p.5, 2005. ,
DOI : 10.1176/jnp.14.3.329
Dopamine D2 Receptor Occupancy and Clinical Effects, Journal of Clinical Psychopharmacology, vol.31, issue.4, pp.497-502, 2011. ,
DOI : 10.1097/JCP.0b013e3182214aad
Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism, Parkinsonism & Related Disorders, vol.20, issue.7, pp.738-780 ,
DOI : 10.1016/j.parkreldis.2014.03.024
Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum, Brain Research, vol.995, issue.1, pp.14-22, 2004. ,
DOI : 10.1016/j.brainres.2003.09.040
Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism, Mol Pharmacol, vol.45, issue.1, pp.158-63, 1994. ,
Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons, Journal of Biological Chemistry, vol.278, issue.44, pp.43628-43663, 2003. ,
DOI : 10.1074/jbc.M308947200
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice, Neuropharmacology, vol.49, issue.2, pp.208-227, 2005. ,
DOI : 10.1016/j.neuropharm.2005.03.003
Striatal Neuroinflammation Promotes Parkinsonism in Rats, PLoS ONE, vol.16, issue.5, p.5482, 2009. ,
DOI : 10.1371/journal.pone.0005482.s003
Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes, Front Neurol, vol.6, p.27, 2015. ,
Traitement m??dicamenteux de la maladie de Parkinson ?? la phase pr??coce (de novo et ????lune de miel????), Revue Neurologique, vol.170, issue.4, pp.237-283 ,
DOI : 10.1016/j.neurol.2013.10.015
Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson???s Disease1, Journal of Parkinson's Disease, vol.5, issue.4, pp.847-53, 2015. ,
DOI : 10.3233/JPD-150532
The spectrum of levodopa-induced dyskinesias, Ann Neurol, vol.47, issue.4, pp.2-9, 2000. ,
Priming for l-dopa-induced dyskinesia in Parkinson???s disease: A feature inherent to the treatment or the disease?, Progress in Neurobiology, vol.87, issue.1, pp.1-9, 2009. ,
DOI : 10.1016/j.pneurobio.2008.09.013
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia, Journal of Neurochemistry, vol.25, issue.2, pp.381-92, 2006. ,
DOI : 10.1016/0166-2236(90)90112-N
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap, The Lancet Neurology, vol.9, issue.11, 2010. ,
DOI : 10.1016/S1474-4422(10)70218-0
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation, Neurobiology of Disease, vol.29, issue.2, 2008. ,
DOI : 10.1016/j.nbd.2007.10.001
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia, Drugs, vol.16, issue.4, pp.759-77 ,
DOI : 10.1007/s40265-016-0566-3
Serotonin and Parkinson's disease: On movement, mood, and madness, Movement Disorders, vol.21, issue.Part 12, pp.1255-66, 2009. ,
DOI : 10.1002/mds.22473
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model, Experimental Neurology, vol.219, issue.1, pp.298-307, 2009. ,
DOI : 10.1016/j.expneurol.2009.05.033
Reduced levodopa-induced complications after 5??years of subthalamic stimulation in Parkinson???s disease: a second honeymoon, Journal of Neurology, vol.66, issue.Pt 11, pp.1736-1777, 2009. ,
DOI : 10.1007/s00415-009-5195-2
Spontaneous Involuntary Disorders of Movement, Archives of General Psychiatry, vol.39, issue.4, pp.452-61, 1982. ,
DOI : 10.1001/archpsyc.1982.04290040052008
Historical perspective on movement disorders, J Clin Psychiatry, vol.65, issue.9, pp.3-8, 2004. ,
Tardive dyskinesia syndromes: current concepts, Parkinsonism & Related Disorders, vol.20, issue.1, pp.113-117 ,
DOI : 10.1016/S1353-8020(13)70028-2
Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76 -338), 1976. ,
Research diagnoses for tardive dyskinesia, Arch Gen Psychiatry, 1982. ,
Evidencebased guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology Jul, vol.3081, issue.5, pp.463-472, 2013. ,
Effects of Amantadine on Tardive Dyskinesia, Clinical Neuropharmacology, vol.33, issue.6, 2010. ,
DOI : 10.1097/WNF.0b013e3181ffde32
Efficacy and Safety of Deep Brain Stimulation in Patients With Medication-Induced Tardive Dyskinesia and/or Dystonia, The Journal of Clinical Psychiatry, vol.73, issue.11, pp.1434-1442, 2012. ,
DOI : 10.4088/JCP.12r07643
Gray Matter Abnormalities in Schizophrenia Patients with Tardive Dyskinesia: A Magnetic Resonance Imaging Voxel-Based Morphometry Study, PLoS ONE, vol.68, issue.8, p.71034, 2013. ,
DOI : 10.1371/journal.pone.0071034.t003
Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study, Movement Disorders, vol.72, issue.5, pp.807-819, 2011. ,
DOI : 10.1002/mds.23660
The Barnes Akathisia Rating Scale???Revisited, Journal of Psychopharmacology, vol.144, issue.4, 2003. ,
DOI : 10.1177/0269881103174013
Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset, Schizophr Res, vol.169, pp.1-3255, 2015. ,
Chronic Restlessness With Antipsychotics, American Journal of Psychiatry, vol.164, issue.11, pp.1648-54, 2007. ,
DOI : 10.1176/appi.ajp.2007.07071150
URL : http://doi.org/10.1176/appi.ajp.2007.07071150
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia, American Journal of Psychiatry, vol.157, issue.4, pp.514-534, 2000. ,
DOI : 10.1176/appi.ajp.157.4.514
Animal models of acute drug-induced akathisia ??? a review, Neuroscience & Biobehavioral Reviews, vol.24, issue.3, pp.269-77, 2000. ,
DOI : 10.1016/S0149-7634(99)00069-X
Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia, in Schizophrenia, Blackwell Scientific Science, pp.552-572, 2003. ,
DOI : 10.1002/9780470987353.ch28
A rating scale for drug-induced akathisia, The British Journal of Psychiatry, vol.154, issue.5, 1989. ,
DOI : 10.1192/bjp.154.5.672
Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia, European Neuropsychopharmacology, vol.15, issue.1, 2005. ,
DOI : 10.1016/j.euroneuro.2004.05.003
Extrapyramidal side-effects of antipsychotics in a randomised trial, The British Journal of Psychiatry, vol.193, issue.4, pp.279-88, 2008. ,
DOI : 10.1192/bjp.bp.108.050088
Neuroleptic-induced acute dystonia American Psychiatric Association, DSM-IV source book, pp.545-559, 1994. ,
Acute dystonia induced by drug treatment, BMJ, 1999. ,
A Meta-Analysis of the Risk of Acute Extrapyramidal Symptoms With Intramuscular Antipsychotics for the Treatment of Agitation, The Journal of Clinical Psychiatry, vol.69, issue.12, pp.1869-79, 2008. ,
DOI : 10.4088/JCP.v69n1204
A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, European Psychiatry, vol.30, issue.6, pp.728-763, 2015. ,
DOI : 10.1016/j.eurpsy.2015.05.004
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-76, 1987. ,
DOI : 10.1093/schbul/13.2.261
URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/13/2/261
A rating scale for mania: reliability, validity and sensitivity, The British Journal of Psychiatry, vol.133, issue.5, pp.429-464, 1978. ,
DOI : 10.1192/bjp.133.5.429
Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry, pp.39-44, 1993. ,
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder, Schizophrenia Research, vol.100, issue.1-3, pp.1-360, 2008. ,
DOI : 10.1016/j.schres.2007.12.470
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method, Schizophrenia Bulletin, vol.40, issue.2, pp.314-340, 2014. ,
DOI : 10.1093/schbul/sbu001
Neuroleptic Intolerance, Schizophrenia Bulletin, vol.23, issue.4, pp.567-82, 1997. ,
DOI : 10.1093/schbul/23.4.567
Prevalence of Neuroleptic-Induced Movement Disorders in Chronic Schizophrenia Inpatients, American Journal of Psychiatry, vol.161, issue.1, pp.160-163, 2004. ,
DOI : 10.1176/appi.ajp.161.1.160
Prevalence of extrapyramidal effects by neuroleptics in admitted people with schizophrenia]. Enferm Clínica, pp.114-121, 2013. ,
Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies, European Neuropsychopharmacology, vol.25, issue.8, pp.1158-66, 2015. ,
DOI : 10.1016/j.euroneuro.2015.04.003
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis, The International Journal of Neuropsychopharmacology, vol.16, issue.06, pp.1205-1223, 2013. ,
DOI : 10.1017/S1461145712001277
Parsing the components of the psychomotor syndrome in schizophrenia, Acta Psychiatrica Scandinavica, vol.25, issue.4, 2012. ,
DOI : 10.1111/j.1600-0447.2012.01846.x
Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST, European Neuropsychopharmacology, vol.24, issue.9, pp.1500-1505, 2014. ,
DOI : 10.1016/j.euroneuro.2014.07.001
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord Off J Mov Disord Soc, pp.589-98, 2006. ,
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder, Am J Psychiatry, vol.156, issue.4, pp.544-553, 1999. ,
Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs, pp.622-631, 2008. ,
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, vol.70, issue.4, pp.1-46, 2009. ,
Tardive dyskinesia and new antipsychotics, Curr Opin Psychiatry, 2008. ,
DOI : 10.1097/yco.0b013e3282f53132
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, The World Journal of Biological Psychiatry, vol.28, issue.2, pp.2-44, 2013. ,
DOI : 10.4088/JCP.09m05284yel